| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,949 | 1,078 | 21:03 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.08. | Nanoform Finland Oyj: Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide | 304 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | August 05, 2026 at 12:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, announced today that it... ► Artikel lesen | |
| 19.05. | Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology | 799 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST
Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell by... ► Artikel lesen | |
| 12.05. | Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery | 755 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 21.04. | Nanoform Finland Oyj: Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026 | 583 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST
Nanoform Finland Plc (the "Company" or "Nanoform") held its Annual General Meeting for 2026 on April 21, 2026 at the Company's... ► Artikel lesen | |
| 02.03. | Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees | 910 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET
Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's... ► Artikel lesen | |
| 26.02. | Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe | 829 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET
Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more... ► Artikel lesen | |
| 07.01. | Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 | 831 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation.... ► Artikel lesen | |
| 16.12.25 | Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 2030 | 1.654 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm... ► Artikel lesen | |
| 12.11.25 | Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set | 1.881 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET
Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and... ► Artikel lesen | |
| 11.11.25 | Nanoform Finland Oyj: Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License | 1.025 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | November 11, 2025 at 08:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that... ► Artikel lesen | |
| 27.10.25 | Nanoform Finland Oyj: Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma | 1.009 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership... ► Artikel lesen | |
| 14.10.25 | Nanoform Finland Oyj: Nanoform Outlicenses Nanoencorafenib And Signs Development And Commercialisation Agreement With A.forall And IMGA | 1.024 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 14, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| 30.09.25 | Nanoform Finland Oyj: Nanoform Expands Commercial Presence In Asia With A&ls Pharma In South Korea | 1.070 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | September 30, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced it has entered... ► Artikel lesen | |
| 21.08.25 | Nanoform Finland Oyj: Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results | 1.864 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | August 21, 2025 at 08:10:00 EEST
First preliminary pivotal study results supportive for project Nanoenzalutamide to continue to progress towards the markets.... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 18,820 | +0,75 % | Formycon steigert Umsatz deutlich und bestätigt Jahresprognose | Formycon hat im ersten Halbjahr 2026 den Umsatz nahezu verdreifacht und das operative Ergebnis deutlich verbessert. Der Biosimilar-Entwickler bestätigt seine Jahresprognose und meldet wichtige Fortschritte... ► Artikel lesen | |
| VEECO INSTRUMENTS | 45,900 | -0,67 % | VEECO INSTRUMENTS INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| ONTO INNOVATION | 297,50 | +1,54 % | Onto Innovation Completes $720 Million Investment For 27% Stake In Rigaku Holdings | ||
| GAUZY | 0,452 | +5,90 % | Gauzy Ltd. Announces Receipt of Nasdaq Notice Regarding Delayed Filing of Annual Report on Form 20-F | TEL AVIV, Israel, May 26, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced that on May 19, 2026... ► Artikel lesen | |
| KOPIN | 4,137 | -5,72 % | KOPIN CORP - S-8, Securities to be offered to employees in employee benefit plans | ||
| LAMPETIA | 0,163 | 0,00 % | EQS-Adhoc: Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Sonstiges
Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten
16.07.2026 / 22:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| RIBER | 9,820 | -0,61 % | RIBER: FIRST-HALF 2026 BUSINESS ACTIVITY Business growth, resilient order book and continued rollout of ROSIE | FIRST-HALF 2026 BUSINESS ACTIVITYBusiness growth, resilient order book and continued rollout of ROSIE Bezons, July 22, 2026 - 8:00 am - RIBER, the global leader in molecular beam epitaxy (MBE) equipment... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,143 | +20,17 % | FendX Technologies Inc.: FendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter Program | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection... ► Artikel lesen | |
| XTPL | 17,480 | +5,17 % | EQS-News: XTPL S.A.: XTPL receives another order for 10 UPD modules as part of its first industrial deployment in China | Issuer: XTPL S.A.
/ Key word(s): Incoming Orders/Development of Sales
XTPL receives another order for 10 UPD modules as part of its first industrial deployment in China
28.07.2026... ► Artikel lesen | |
| NVE | 105,00 | -0,94 % | NVE CORP /NEW/ - 8-K, Current Report | ||
| SOLESENCE | 1,010 | -3,81 % | Solésence, Inc.: Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results | Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty... ► Artikel lesen | |
| GOMSPACE | 1,107 | +0,18 % | GomSpace A/S: GomSpace Signs 24.4 MSEK Contract with Unseenlabs | Unseenlabs extends its existing cube satellites constellation.STOCKHOLM, July 1, 2026 /PRNewswire/ -- Today, GomSpace has signed an additional contract with Unseenlabs to deliver two new... ► Artikel lesen | |
| NANOVEU | 0,049 | +25,64 % | Daily Special: Iltani Resources, Nanoveu, LTR Pharma, Mont Royal Resources, Lithium Universe | ||
| ACACIA RESEARCH | 3,960 | +1,02 % | ACACIA RESEARCH CORP - 10-Q, Quarterly Report | ||
| ADVANCE ZINCTEK | 0,366 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 16.02.2026 | Das Instrument OYS US68162K1060 OLYMPIC STEEL EQUITY wird cum Kapitalmassnahme gehandelt am 16.02.2026 und ex Kapitalmassnahme am 17.02.2026 The instrument OYS US68162K1060 OLYMPIC STEEL EQUITY is traded... ► Artikel lesen |